Outcome of Systemic Lupus Erythematosus a Study of 66 Patients over 7 Years with Special Reference to the Predictive Value of Anti-DNA Antibody Determinations

Abstract

A cohort of 66 patients with SLE that were thoroughly studied, both clinically and serologically in 1980-81, when they had a mean disease duration of eight years, were evaluated seven years later in order to assess the long-range outcome of the disease. Five patients were lost from follow-up and 12 (20%) died during the follow-up. The estimated 10-year survival was 91%. A total of 30 patients (45%), showed no signs of nephritis at any stage, and in only eight an active nephritis was found during the follow-up. The previous antibody determinations, provided no predictive information regarding the behaviour of the renal manifestations. Arthralgia was the main clinical symptom during the follow-up. Hypertension developed in 23%. At the end of the follow-up the disease was regarded as active in 13% of the patients.

Early renal damage assessed by the SLICC/ACR damage index is predictor of severe outcome in lupus patients in Pakistan

“…The kidneys were the commonest organ being damaged (37.5%), followed by the CNS (28%), skin (28.5%) and musculoskeletal systems (25.5%). Median SLICC score of the whole cohort was 1 (range 0-5) and for those who had damage, median SLICC score was 2 (range [1][2][3][4][5]. No significant difference in DS could be demonstrated between female and male patients (p < 0.84).…”

Low diagnostic and predictive value of anti-dsDNA antibodies in unselected patients with recent onset of rheumatic symptoms: results from a long-term follow-up Scandinavian multicentre study

“…Both the detection and measurement of anti-double-stranded DNA (anti-dsDNA) antibodies are considered essential to diagnosing SLE, to assessing its phenotype, especially renal involvement (1), and to determining its activity (2)(3)(4)(5)(6). Previous studies have indicated that patients with nonspecific clinical manifestations run a considerable risk of developing SLE within 5 years after the first detection of anti-DNA antibodies (7,8).…”

Relationship Between Flare and Health-related Quality of Life in Patients with Systemic Lupus Erythematosus

“…Flare is an important outcome in SLE because uncontrolled disease activity and toxicity of therapies will result in disease damage, which is a major determinant of longterm prognosis [8][9][10] . Flare can be quantified using the existing disease activity indices.…”